
The secret to living longer may be the immune system's 'fountain of youth' - but it comes at a price
For some over 60s with 'immune youth' have specialised white blood cells that restore strength and muscle mass, scientists have discovered.
According to US researchers, who tracked more than 100 older adults, these cells known as Stem-like T cells, give people younger immune systems.
But they also discovered those with the cells, also called stem-like memory T cells or TSL, could spread disease more easily.
Instead, those with such cells were more likely to have autoimmunity—when the immune system mistakenly attacks healthy tissues and organs instead of defending it.
Dr Cornelia Weyand, a rheumatologist, expert in immune cell function at the Mayo Clinic in Minnesota and study co-author, said: 'We observed that these patients have very young immune systems despite being in their 60s and 70s.
'But the price they pay for that is autoimmunity.'
Dr Jörg Goronzy, an immunologist at the Mayo Clinic and study co-author, added: 'Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body.
'We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease.'
In the study, researchers tracked the 100 over 60s who attended the Mayo Clinic to receive treatment for giant cell arteritis, an autoimmune disease that affects the arteries, including the aorta.
Writing in the journal Nature Aging, they said they found stem-like T cells in the diseased tissue of these patients.
They also discovered the immune checkpoint inhibitors that regulate the immune system were not working properly.
The scientists said they are now in the process of developing new diagnostic tests that will help find patients and healthy individuals who carry high numbers of immune stem cells and may be predisposed to autoimmune disease later in life.
Last year, research suggested life expectancy across the world will rise by almost five years by 2050, with the average man forecasted to live to 76 and woman, past 80.
Global average life expectancy is forecast to increase to around 78.1 years of age in 2050, a rise of 4.5 years, The Lancet Public Health study also found.
At the time, experts said the trend was largely driven by public health measures both preventing and improving survival rates from illnesses including cardiovascular disease, nutritional diseases and maternal and neonatal infections.
Commentators also said the figures present an 'immense opportunity' to 'get ahead of rising metabolic and dietary risk factors' such as high blood pressure and BMI.
The oldest living person in the world is now believed to be Ethel Caterham, from Surrey, who was born on August 21, 1909 and is 115 years old.
The title of the oldest person to have ever lived belongs to French woman Jeanne Louise Calment whose life spanned 122 years and 164 days.
Ms Caterham, who died in 1997, attributed her longevity to 'never arguing with anyone, I listen and I do what I like'.
Experts who have studied centenarians agree.
Physical activity, faith, love, companionship, and a sense of purpose make up the backbone of so-called 'Blue Zones,' or areas of the world where people typically live to 100 and beyond.
Maintaining an active lifestyle, even simply walking around town every day, has been shown to improve longevity.
Companionship has been shown to have a similarly positive effect on a person's lifespan, with studies consistently showing loneliness is toxic.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medical News Today
an hour ago
- Medical News Today
Experimental drug eliminates aggressive breast, skin cancer in small trial
Scientists have developed a new cancer drug that can be injected directly into tumors. The treatment, an enhanced CD40 agonist, was successful in its first trial of 12 human participants. Six people in the group saw their tumors shrink, while two participants saw their cancer go completely into remission. The National Institutes of Health project that doctors will diagnose at least 2 million new cancer cases and that 600,000 people will die from cancer in 2025 in the United improving cancer death rates, this prediction highlights the need to continue developing more effective treatments. Researchers from Rockefeller University made headway in this area with the completion of their human phase 1 study. They tested a new CD40 antibody drug, 2141-V11, designed to shrink tumors and reduce side new drug had promising results, shrinking tumors in half the patients and completely eliminating cancer in two cases, while not causing serious side effects. The study appears in the journal Cancer Cell.A new approach to cancer immunotherapyMany cancer treatments exist, and sometimes treatment can be as simple as removing the tumor or lesion for localized cancers. In cases where the cancer is metastatic and has spread, more aggressive treatments are necessary. Some types of more aggressive cancer treatments include: radiation therapychemotherapyhormone American Cancer Society describes immunotherapy as a 'treatment that uses the body's immune system, usually your own, to attack cancer.' There are several types of immunotherapy, such as immune checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Researchers in the new study focused on immunotherapy — specifically, the CD40 agonist antibody drug class, a type of monoclonal antibody treatment. It works by activating the CD40 receptor and causing an immune system response. According to the study authors, research on CD40 has not been successful in human trials in the past and has caused serious side effects. This led the scientists to create an engineered form of CD40 called 2141-V11. The drug was designed to improve the issues with CD40 and reduce systemic inflammation and liver toxicity. The scientists also decided to inject the treatment directly into the tumor instead of administering it intravenously. For the human study, the researchers recruited 12 participants, and everyone in the group had metastatic cancers including melanoma and breast cancer. The participants ranged from ages 42 to participants received injections of 2141-V11 into their tumors every 3 weeks, with an increased dosage each results with limited toxicityThroughout the 2141-V11 treatments, the researchers monitored the side effects and bloodwork of the participants. They were especially concerned with the participants' platelet count and liver enzymes since these would indicate a treatment-related adverse event (TRAE). By the end of the treatment, ten participants experienced adverse events, and seven experienced TRAEs. However, none of the patients experienced any TRAEs higher than grade 3, and the researchers considered the drug 'well tolerated.' Most of the side effects were mild and included fever and issues where the drug was injected. Three participants had severe adverse events, but the researchers did not consider them TRAEs. One participant had to be hospitalized because of a urinary tract infection, and another had shortness of breath related to chronic heart failure. No serious dose-limiting toxicities occurred, and the participants' liver and platelet levels were stable throughout treatment. Additionally, cancer tumors shrank in six of the participants, and two participants went into complete remission. One of the participants who went into remission had melanoma, and the other had breast cancer. The researchers noted that not only did their tumors shrink, but tumors in the rest of the body disappeared. Wael Harb, MD, a board-certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers, spoke with Medical News Today and explained how the cancer drug works.'This drug (2141-V11) is an engineered antibody that flips a key 'ON' switch (CD40) on immune cells inside a tumor,' said Harb, who was not involved in the recent trial. 'It's injected directly into one tumor, where it organizes immune cells into mini lymph nodes called tertiary lymphoid structures (TLS).' 'Those act like on-site training camps that activate cancer-killing T-cells, which then travel through the body to attack tumors that weren't injected,' Harb he noted that the drug's safety profile was encouraging, he emphasized that larger trials are needed. 'Twelve patients are too few to draw firm safety conclusions across cancers–larger trials are needed and are already underway,' the oncologist is next for 2141-V11?Study author Juan Osorio, MD, director Of Clinical Operations And Translational Immunology at Rockefeller University, spoke with MNT and discussed the future of the research with 2141-V11. 'We look forward to the results of several ongoing phase 2 studies nationwide, targeting difficult-to-treat cancers, such as malignant gliomas, bladder cancer, and prostate cancer,' said Osorio. Osorio mentioned that early data from the phase 2 studies is 'promising,' but it is not a one-size-fits-all solution for people with cancer. 'Not all patients respond, highlighting the need for rational combination strategies to extend the benefit of this therapy,' Osorio shared. Osorio said the team is currently trying to figure out which biomarkers may predict response to CD40 agonists. 'Furthermore, we want to evaluate in larger cohorts whether TLS or other immune spatial interactions are crucial for effective induction of antitumor immunity. Answering these questions will be critical to fully translate this approach into meaningful and durable clinical benefit for patients.'

Western Telegraph
an hour ago
- Western Telegraph
Mounjaro prices double as weight loss jab popularity soars
US-based Eli Lilly says a 5mg dose will nearly double from £92 to £180 from September 1, while a 15mg pen will rise from £122 to £330. A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access." The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability." More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Recommended reading: Mounjaro warning as pens ruined by heatwave temperatures This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave. Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal. 'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.' 8 tips to protect Mounjaro and other weight-loss injections during hot weather Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces. Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective. 'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."


Daily Mail
2 hours ago
- Daily Mail
Mass poisoning. Mind control. And weather tampering. The TRUTH about 'chemtrails'
The white lines seen following airplanes as they fly could be full of harmful chemicals that are toxic in Americans' health, some people claim. The streaks left across the sky from planes, called contrails, are formed by water vapor from the plane's exhaust freezing in the cold air at high altitudes. Your browser does not support iframes.